ILMN Illumina, Inc. Stock Quote

ILMN [NASD]

Healthcare | Diagnostics & Research | USA

Index	S&P 500	P/E	118.34	EPS (ttm)	4.26	Insider Own	0.30%	Shs Outstand	146.00M	Perf Week	2.52%
Market Cap	73.06B	Forward P/E	69.90	EPS next Y	7.22	Insider Trans	-7.86%	Shs Float	145.62M	Perf Month	6.27%
Income	630.00M	PEG	5.80	EPS next Q	1.36	Inst Own	92.70%	Short Float	1.63%	Perf Quarter	33.37%
Sales	3.47B	P/S	21.04	EPS this Y	-34.10%	Inst Trans	0.21%	Short Ratio	3.59	Perf Half Y	20.09%
Book/sh	33.71	P/B	14.97	EPS next Y	19.48%	ROA	8.10%	Target Price	406.44	Perf Year	28.18%
Cash/sh	31.98	P/C	15.78	EPS next 5Y	20.40%	ROE	13.30%	52W Range	260.42 - 555.77	Perf YTD	36.38%
Dividend	-	P/FCF	82.09	EPS past 5Y	7.40%	ROI	6.50%	52W High	-9.21%	Beta	0.92
Dividend %	-	Quick Ratio	4.20	Sales past 5Y	7.90%	Gross Margin	67.60%	52W Low	93.76%	ATR	10.51
Employees	7800	Current Ratio	4.40	Sales Q/Q	27.20%	Oper. Margin	16.80%	RSI (14)	67.98	Volatility	1.84% 2.40%
Optionable	Yes	Debt/Eq	0.44	EPS Q/Q	-14.50%	Profit Margin	18.10%	Rel Volume	1.32	Prev Close	498.42
Shortable	Yes	LT Debt/Eq	0.34	Earnings	Aug 05 AMC	Payout	0.00%	Avg Volume	663.32K	Price	504.60
Recom	2.80	SMA20	4.60%	SMA50	9.90%	SMA200	26.00%	Volume	876,490	Change	1.24%

Jun-01-21

Upgrade

Evercore ISI

Underperform → In-line

$400

Mar-31-21

Upgrade

Canaccord Genuity

Hold → Buy

$445

Mar-31-21

Downgrade

Atlantic Equities

Overweight → Neutral

$390

Mar-03-21

Initiated

Barclays

Underweight

$325

Dec-22-20

Upgrade

Piper Sandler

Neutral → Overweight

$340 → $415

Dec-17-20

Upgrade

BTIG Research

Neutral → Buy

$410

Oct-13-20

Downgrade

Guggenheim

Buy → Neutral

Sep-30-20

Initiated

Atlantic Equities

Overweight

$355

Sep-29-20

Downgrade

Wolfe Research

Outperform → Peer Perform

Sep-22-20

Downgrade

UBS

Buy → Neutral

$390 → $285

Sep-22-20

Downgrade

Stifel

Buy → Hold

$380 → $280

Sep-21-20

Upgrade

Guggenheim

Neutral → Buy

$345

Sep-21-20

Downgrade

JP Morgan

Overweight → Neutral

$390 → $280

Sep-09-20

Initiated

Morgan Stanley

Equal-Weight

$400

Aug-07-20

Downgrade

Piper Sandler

Overweight → Neutral

$356 → $340

Aug-07-20

Downgrade

Evercore ISI

In-line → Underperform

$310

Jul-07-20

Downgrade

Guggenheim

Buy → Neutral

Apr-24-20

Downgrade

Citigroup

Buy → Neutral

$250 → $320

Apr-21-20

Downgrade

Robert W. Baird

Outperform → Neutral

$310

Jan-08-20

Initiated

Wells Fargo

Underweight

$300

Aug-04-21 12:52PM	Is Illumina (ILMN) an Interesting Stock to Buy? Insider Monkey
10:39AM	Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN Zacks
Aug-03-21 09:30PM	Illumina Donates $1 Million in Sequencing Capabilities to Mumbai to Support Sequencing-Based COVID-19 Surveillance in India PR Newswire
Jul-30-21 06:35AM	3 Things About Illumina That Smart Investors Know Motley Fool
Jul-29-21 03:05PM	Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
06:55AM	After Naming a New CFO, Is This Genetic Diagnostics Company a Buy? Motley Fool
Jul-28-21 06:30PM	Illumina to Webcast Upcoming Investor Conference Business Wire
Jul-26-21 08:50AM	How Investors Can Grab Better Returns for Medical Using the Zacks ESP Screener Zacks
Jul-23-21 12:28PM	Illumina-Grail $8B Merger Hit By European Commission's In-Depth Investigation Benzinga
06:00AM	Scottish Mortgage backs these vaccine pioneers to become the next Amazon The Telegraph
Jul-22-21 12:49PM	Illumina is Committed to Bringing Lifesaving GRAIL Test to People Globally as European Review Process Enters Second Phase Business Wire
12:39PM	Is Illumina (ILMN) A Smart Long-Term Buy? Insider Monkey
12:31PM	UPDATE 3-Illumina deal for Grail could hurt innovation, EU warns Reuters
12:19PM	Illumina deal for Grail could hurt innovation, EU warns Reuters
12:19PM	EU antitrust regulators to investigate Illumina, Grail deal Reuters
12:15PM	EU antitrust regulators to investigate Illumina, Grail deal Reuters
Jul-21-21 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Illumina (ILMN) Zacks
03:21AM	Is Illumina's (NASDAQ:ILMN) Share Price Gain Of 225% Well Earned? Simply Wall St.
Jul-20-21 12:10PM	Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive? Zacks
12:00PM	All You Need to Know About Illumina (ILMN) Rating Upgrade to Buy Zacks
Jul-19-21 07:07AM	Dante Labs appoints Illumina acclaimed COO Bob Ragusa as Board Member to support the execution of its global integrated precision medicine strategy GlobeNewswire
Jul-14-21 11:50AM	Illumina, Grail Merger Faces Full-Scale European Probe Amid Antitrust Concerns: Reuters Benzinga
07:31AM	Is Illumina a Buy? Motley Fool
Jul-13-21 08:00PM	Competition enforcement is harder than it looks Financial Times
05:00PM	Illumina to Announce Second Quarter 2021 Financial Results on Thursday, August 5, 2021 Business Wire
03:18PM	Exclusive-Illumina, Grail deal faces full-scale EU antitrust probe -sources Reuters
Jul-08-21 04:44PM	Why Illumina Was Up 17% in June Motley Fool
Jul-03-21 09:00AM	5 Top Stocks for July Motley Fool
Jun-30-21 11:30AM	Is Illumina (ILMN) Outperforming Other Medical Stocks This Year? Zacks
Jun-28-21 01:12PM	Investors Ritzy Habits Are Food for Thought for Insider Jury Bloomberg
Jun-25-21 11:58AM	Accused Fraudster Tapped Firm Account for Strip Club Visit Bloomberg
Jun-22-21 10:03AM	Illumina's (ILMN) NovaSeq Adoption Aids, Margin Woe Stays Zacks
Jun-18-21 08:22PM	Why Moderna, Illumina, or Meituan Could Be the Next Tesla Stock Barrons.com
04:13PM	Why Moderna, Illumina, or Chinas Meituan Could Be the Next Tesla Barrons.com
Jun-17-21 10:36AM	Hedge Funds Are Buying Illumina, Inc. (ILMN) Insider Monkey
05:34AM	EU antitrust regulators set July 27 deadline for Illumina, Grail deal Reuters
Jun-12-21 06:10AM	Has Illumina Lost Its Shine? Motley Fool
Jun-10-21 08:00AM	DNA Data Storage Alliance Publishes First White Paper, Launches Website Business Wire
06:43AM	The Zacks Analyst Blog Highlights: Intel, NextEra Energy, PetroChina, Illumina and Biogen Zacks
Jun-09-21 09:08AM	Let's Shine a Light on Illumina's Breakout TheStreet.com
06:47AM	Will Illumina Be a Trillion-Dollar Stock by 2035? Motley Fool
Jun-04-21 12:55PM	This Biotech Just Made History. Will Its Stock Follow? Motley Fool
09:09AM	Grail Will Begin Selling Its Multi-Cancer Blood Test. It Could Be the Start of a Huge Market. Barrons.com
08:37AM	2 Winners for a Drug Development Future That Looks Nothing Like the Past Motley Fool
Jun-01-21 07:40AM	Illumina (ILMN) Expands NIPT Offering With New Collaboration Zacks
03:05AM	Illumina Supports Nationwide Program across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Diagnosis Business Wire
May-31-21 08:00PM	Illumina accuses US regulators of time-wasting over $8bn Grail deal Financial Times
04:00PM	Illumina and Next Generation Genomic Partner to Launch VeriSeq NIPT Solution in Thailand Business Wire
10:45AM	BD (BDX) to Boost Lab Efficacy With BD Kiestra UCA's U.S. Launch Zacks
07:24AM	Cooper Companies (COO) to Post Q2 Earnings: What's in Store? Zacks
May-29-21 07:07AM	Could Bionano Genomics Be a Millionaire-Maker Stock? Motley Fool
06:45AM	2 Top Biotech Picks to Buy and Hold for the Next 10 Years Motley Fool
May-28-21 01:27PM	Is It Too Late to Buy Illumina (ILMN) Stock? Insider Monkey
09:31AM	Change Healthcare (CHNG) Q4 Earnings & Revenues Top Estimates Zacks
May-27-21 05:00PM	Illumina To Webcast Upcoming Investor Conference Business Wire
11:31AM	Illumina (ILMN) Down 1.9% Since Last Earnings Report: Can It Rebound? Zacks
05:53AM	QIAGEN (QGEN)-Mirati Deal to Boost Companion Diagnostic Arm Zacks
May-25-21 11:30AM	Is Illumina (ILMN) Outperforming Other Medical Stocks This Year? Zacks
May-22-21 04:50AM	Should Weakness in Illumina, Inc.'s (NASDAQ:ILMN) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? Simply Wall St.
May-20-21 07:27AM	The Zacks Analyst Blog Highlights: PulteGroup, Weyerhaeuser, General Motors, Illumina and Marriott International Zacks
May-19-21 08:04AM	Top 5 S&P 500 Stocks at Lucrative Valuation Amid May Turmoil Zacks
07:22AM	STERIS (STE) Q4 Earnings Fall Shy of Estimates, FY22 View Up Zacks
May-18-21 10:27AM	Questor: Illumina cracked the Covid code and tracks the variants but thats not why its a buy The Telegraph
May-17-21 04:05PM	Telos Corporation Reports First Quarter 2021 Results GlobeNewswire
02:45PM	Telos Corp to Host Earnings Call ACCESSWIRE
10:00AM	National Vision (EYE) Q1 Earnings Top Estimates, View Up Zacks
08:05AM	Illumina Appoints Susan Tousi as Chief Commercial Officer and Dr. Alex Aravanis as Chief Technology Officer, Head of Research and Product Development Business Wire
07:24AM	Haemonetics (HAE) Q4 Earnings Lag Estimates, Gross Margin Dips Zacks
May-13-21 06:16AM	3 Cathie Wood Stocks for a $150 Billion Market That's Just Forming Motley Fool
05:30AM	Telos Corporation Awarded $35 Million U.S. Army Contract for Systems on Korean Peninsula GlobeNewswire
May-11-21 10:59AM	Cardiovascular Systems (CSII) Q3 Loss Widens, Gross Margin Dips Zacks
09:35AM	Here's Why You Should Hold on to Illumina (ILMN) Stock for Now Zacks
07:50AM	Intersect ENT (XENT) Q1 Loss Wider Than Expected, Revenues Top Zacks
May-10-21 02:25PM	Was The Smart Money Right About Illumina, Inc. (ILMN)? Insider Monkey
May-07-21 08:59AM	Phibro (PAHC) Q3 Earnings Beat Estimates, Margins Decline Zacks
May-06-21 08:57AM	Tandem Diabetes (TNDM) Q1 Net Loss Narrows, Guidance Up Zacks
08:55AM	NuVasive (NUVA) Q1 Earnings Top Estimates, Gross Margin Up Zacks
07:24AM	Cerner (CERN) Q1 Earnings Beat Estimates, Revenues Miss Zacks
06:14AM	Why Does Cathie Wood Like This Healthcare Stock So Much? Motley Fool
May-05-21 08:29AM	Exact Sciences (EXAS) Q1 Earnings Top Estimates, Margins Down Zacks
08:26AM	PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates Zacks
08:25AM	Globus Medical (GMED) Q1 Earnings Beat Estimates, Margins Up Zacks
08:24AM	AmerisourceBergen (ABC) Q2 Earnings Beat, Revenues Miss Zacks
07:01AM	Is Illumina Sandbagging With Its Full-Year Guidance? Motley Fool
May-04-21 06:09PM	Shares of Cancer Researchers Exact Sciences and Invitae Are Sliding. Heres Why. Barrons.com
11:59AM	Zimmer Biomet (ZBH) Q1 Earnings Top, Operating Margin Up Zacks
11:27AM	CVS Health (CVS) Q1 Earnings Beat Estimates, EPS View Up Zacks
08:16AM	QIAGEN (QGEN) Q1 Earnings Beat Estimates, 2021 Guidance Up Zacks
May-03-21 04:05PM	Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives GlobeNewswire
09:24AM	Hill-Rom (HRC) Q2 Earnings Surpass Estimates, Margins Up Zacks
Apr-30-21 02:00PM	2 of the Best Healthcare Stocks You'll Find Today Motley Fool
08:46AM	How Britain leads the world in Covid sequencing The Telegraph
Apr-29-21 05:30PM	Illumina To Webcast Upcoming Investor Conference Business Wire
09:05AM	Illumina Files Action for Annulment of European Commissions Decision Asserting Jurisdiction to Review GRAIL Acquisition Business Wire
Apr-28-21 08:00PM	Illumina sues Brussels over probe into $8bn cancer deal for Grail Financial Times
09:39AM	Illumina (ILMN) Q1 Earnings Top Estimates, Margins Decline Zacks
09:05AM	Illumina to Donate US $60 Million in Sequencing Capabilities to Establish a Global Pathogen Genomics Initiative Business Wire
06:04AM	How Illumina's Q1 Results Delighted Investors Motley Fool
12:00AM	Illumina Inc (ILMN) Q1 2021 Earnings Call Transcript Motley Fool
Apr-27-21 05:37PM	Illumina Rises On Quarterly Beat, Strong Outlook; Reaffirms Grail Buyout Investor's Business Daily

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TOUSI SUSAN H	SVP, Chief Commercial Officer	Jul 28	Sale	486.41	300	145,923	42,743	Jul 29 04:34 PM
Dadswell Charles	SVP & General Counsel	Jul 22	Sale	482.23	314	151,420	5,576	Jul 26 04:57 PM
Aravanis Alexander	SVP, Chief Technology Officer	Jul 07	Sale	477.59	539	257,421	4,679	Jul 07 06:26 PM
TOUSI SUSAN H	SVP, Chief Commercial Officer	Jun 28	Sale	478.95	300	143,685	43,043	Jun 30 05:27 PM
Dadswell Charles	SVP & General Counsel	Jun 22	Sale	461.01	314	144,757	5,890	Jun 24 05:41 PM
Febbo Phillip G.	SVP Chief Medical Officer	Jun 11	Sale	447.59	1,000	447,588	4,461	Jun 14 05:50 PM
DORSA CAROLINE	Director	Jun 10	Sale	450.00	1,000	450,000	8,501	Jun 14 05:48 PM
Dadswell Charles	SVP & General Counsel	May 24	Sale	403.04	314	126,555	6,204	May 26 04:50 PM
TOUSI SUSAN H	SVP, Chief Commercial Officer	May 20	Sale	400.00	500	200,000	43,343	May 24 04:43 PM
FLATLEY JAY T	Director	May 18	Sale	379.53	4,000	1,518,120	148,933	May 20 04:51 PM
TOUSI SUSAN H	SVP Product Development	May 05	Sale	381.88	300	114,564	43,843	May 06 05:26 PM
FLATLEY JAY T	Director	May 04	Sale	384.15	4,000	1,536,600	152,933	May 06 05:21 PM
Dadswell Charles	SVP & General Counsel	Apr 22	Sale	402.02	314	126,234	6,518	Apr 26 07:52 PM
FLATLEY JAY T	Director	Apr 20	Sale	401.83	4,000	1,607,320	156,933	Apr 22 05:05 PM
FLATLEY JAY T	Director	Apr 06	Sale	423.44	4,000	1,693,740	160,933	Apr 07 04:41 PM
TOUSI SUSAN H	SVP Product Development	Apr 06	Sale	423.44	500	211,718	44,143	Apr 07 04:34 PM
TOUSI SUSAN H	SVP Product Development	Apr 05	Sale	386.03	300	115,809	44,643	Apr 07 04:34 PM
Dadswell Charles	SVP & General Counsel	Mar 22	Sale	416.24	314	130,699	6,832	Mar 24 04:41 PM
FLATLEY JAY T	Director	Mar 16	Sale	421.06	4,000	1,684,240	164,933	Mar 18 07:20 PM
TOUSI SUSAN H	SVP Product Development	Mar 05	Sale	402.24	800	321,792	44,943	Mar 09 05:29 PM
FLATLEY JAY T	Director	Mar 02	Sale	444.61	4,000	1,778,440	168,933	Mar 04 05:04 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Feb 18	Sale	486.75	666	324,176	1,538	Feb 22 05:11 PM
TOUSI SUSAN H	SVP Product Development	Feb 17	Option Exercise	0.00	6,306	0	48,921	Feb 18 04:52 PM
SAMAD SAM	SVP and CFO	Feb 17	Option Exercise	0.00	4,379	0	9,355	Feb 18 04:51 PM
RAGUSA ROBERT P	SVP, Global Quality & Ops	Feb 17	Option Exercise	0.00	6,306	0	12,795	Feb 18 04:49 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Feb 17	Option Exercise	0.00	935	0	2,576	Feb 18 04:47 PM
Hoyt Aimee L	SVP, Chief People Officer	Feb 17	Option Exercise	0.00	4,625	0	8,873	Feb 18 04:45 PM
Febbo Phillip G.	SVP Chief Medical Officer	Feb 17	Option Exercise	0.00	3,173	0	7,046	Feb 18 04:44 PM
deSouza Francis A	President and CEO	Feb 17	Option Exercise	0.00	24,521	0	85,934	Feb 18 04:42 PM
Dadswell Charles	SVP & General Counsel	Feb 17	Option Exercise	0.00	3,503	0	8,781	Feb 18 04:41 PM
FLATLEY JAY T	Director	Feb 16	Sale	495.09	500	247,543	3,500	Feb 18 07:08 PM
FLATLEY JAY T	Director	Feb 16	Sale	505.26	4,000	2,021,040	172,933	Feb 18 07:08 PM
TOUSI SUSAN H	SVP Product Development	Feb 05	Sale	431.90	800	345,520	39,713	Feb 09 04:48 PM
Hoyt Aimee L	SVP, Chief People Officer	Feb 02	Sale	444.84	57	25,356	2,359	Feb 03 05:00 PM
FLATLEY JAY T	Director	Feb 02	Sale	444.84	4,000	1,779,360	176,933	Feb 03 04:58 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Feb 02	Sale	444.84	72	32,028	1,538	Feb 03 04:57 PM
deSouza Francis A	President and CEO	Feb 01	Sale	439.78	3,000	1,319,330	52,603	Feb 03 04:56 PM
TOUSI SUSAN H	SVP Product Development	Jan 20	Sale	400.00	2,500	1,000,000	40,447	Jan 21 04:40 PM
FLATLEY JAY T	Director	Jan 19	Sale	382.48	4,000	1,529,920	180,933	Jan 21 04:38 PM
Hoyt Aimee L	SVP, Chief People Officer	Jan 11	Sale	379.65	271	102,885	2,359	Jan 12 04:41 PM
TOUSI SUSAN H	SVP Product Development	Jan 05	Sale	365.27	300	109,581	42,947	Jan 06 07:20 PM
FLATLEY JAY T	Director	Jan 05	Sale	365.27	4,000	1,461,080	184,933	Jan 06 07:19 PM
deSouza Francis A	President and CEO	Jan 04	Sale	370.51	3,000	1,111,537	55,540	Jan 06 07:17 PM
FLATLEY JAY T	Director	Dec 15	Sale	348.84	4,000	1,395,360	188,933	Dec 16 06:07 PM
Hoyt Aimee L	SVP, Chief People Officer	Dec 14	Sale	345.00	354	122,130	2,744	Dec 16 06:05 PM
Ronaghi Mostafa	SVP, Entrepreneurial Devlopmt	Dec 10	Sale	338.58	5,000	1,692,922	80,162	Dec 14 04:12 PM
TOUSI SUSAN H	SVP Product Development	Dec 07	Sale	349.34	300	104,803	43,247	Dec 08 05:34 PM
TOUSI SUSAN H	SVP Product Development	Dec 04	Sale	350.00	200	70,000	43,547	Dec 08 05:34 PM
Dadswell Charles	SVP & General Counsel	Dec 01	Sale	323.86	1,694	548,619	3,460	Dec 02 05:48 PM
deSouza Francis A	President and CEO	Dec 01	Sale	327.95	3,000	983,851	58,540	Dec 02 05:45 PM
TOUSI SUSAN H	SVP Product Development	Dec 01	Sale	325.00	100	32,500	43,747	Dec 02 05:41 PM
FLATLEY JAY T	Director	Dec 01	Sale	323.90	4,000	1,295,590	192,933	Dec 02 05:37 PM
RAGUSA ROBERT P	SVP, Global Quality & Ops	Nov 30	Sale	314.82	2,890	909,827	4,092	Dec 02 05:34 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Nov 18	Sale	300.00	218	65,400	1,538	Nov 19 04:16 PM
FLATLEY JAY T	Director	Nov 17	Sale	297.16	3,000	891,470	196,933	Nov 19 04:18 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Nov 06	Sale	310.10	312	96,751	1,872	Nov 09 05:40 PM
Hoyt Aimee L	SVP, Chief People Officer	Nov 06	Sale	310.10	215	66,672	3,098	Nov 09 05:39 PM
Febbo Phillip G.	SVP Chief Medical Officer	Nov 06	Sale	310.10	155	48,066	2,143	Nov 09 05:35 PM
FLATLEY JAY T	Director	Nov 03	Sale	297.34	3,000	892,010	199,933	Nov 04 04:43 PM
deSouza Francis A	President and CEO	Nov 02	Sale	300.28	3,000	900,852	65,840	Nov 04 04:39 PM
Dadswell Charles	SVP & General Counsel	Nov 02	Sale	298.00	121	36,058	6,036	Nov 04 04:34 PM
FLATLEY JAY T	Director	Oct 20	Sale	321.71	4,000	1,286,860	202,933	Oct 22 03:47 PM
TOUSI SUSAN H	SVP Product Development	Oct 12	Sale	350.00	200	70,000	44,968	Oct 14 04:07 PM
TOUSI SUSAN H	SVP Product Development	Oct 07	Sale	325.00	100	32,500	45,168	Oct 08 05:21 PM
FLATLEY JAY T	Director	Oct 07	Sale	324.01	1,000	324,010	206,933	Oct 08 05:18 PM
FLATLEY JAY T	Director	Oct 06	Sale	317.79	3,000	953,370	207,933	Oct 07 04:49 PM
deSouza Francis A	President and CEO	Oct 01	Sale	308.78	3,000	926,331	68,840	Oct 05 05:14 PM
Dadswell Charles	SVP & General Counsel	Oct 01	Sale	312.82	121	37,851	6,157	Oct 05 05:11 PM
FLATLEY JAY T	Director	Sep 15	Sale	355.22	4,000	1,420,880	210,933	Sep 17 04:59 PM
TOUSI SUSAN H	SVP Product Development	Sep 09	Sale	350.00	200	70,000	45,268	Sep 10 04:49 PM
TOUSI SUSAN H	SVP Product Development	Sep 08	Sale	336.00	100	33,600	45,468	Sep 10 04:49 PM
Van Oene Mark	SVP Chief Commercial Officer	Sep 01	Sale	355.13	625	221,953	17,648	Sep 02 07:52 PM
deSouza Francis A	President and CEO	Sep 01	Sale	352.32	3,000	1,056,964	71,840	Sep 02 07:49 PM
Dadswell Charles	SVP & General Counsel	Sep 01	Sale	355.35	1,687	599,475	6,278	Sep 02 07:45 PM
FLATLEY JAY T	Director	Sep 01	Sale	355.35	4,000	1,421,400	214,933	Sep 02 07:35 PM
RAGUSA ROBERT P	SVP, Global Quality & Ops	Aug 31	Sale	355.18	5,000	1,775,907	8,103	Sep 02 07:29 PM
FLATLEY JAY T	Director	Aug 18	Sale	354.03	4,000	1,416,120	218,933	Aug 20 05:14 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Aug 10	Sale	357.01	1,856	662,611	2,350	Aug 12 04:32 PM
TOUSI SUSAN H	SVP Product Development	Aug 05	Sale	399.02	800	319,220	45,568	Aug 06 04:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience